Press releasePRNewswire
Compugen
CGEN · NASDAQ
$2.14+$0.17 (+8.63%)TodayMarket closed ·
Prev close $1.97
Latest news
- Press releasePRNewswire
Compugen to Host Virtual KOL Event on COM701 in Ovarian Cancer & Unigen™ Platform Update on October 5, 2026
- Press releasePRNewswire
Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference
- Press releasePRNewswire
Compugen Reports Second Quarter 2026 Results
- Press releasePRNewswire
Compugen to Participate in BTIG Biotechnology Conference 2026
- Press releasePRNewswire
Compugen to Release Second Quarter 2026 Results on Monday, August 3, 2026
- Press releasePRNewswire
Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress
- Press releasePRNewswire
Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026
- Press releasePRNewswire
Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development
- News
Compugen Q1 2026 Earnings Call: Complete Transcript
- News
Earnings Scheduled For May 18, 2026
- Press releasePRNewswire
Compugen Reports First Quarter 2026 Results
- Press releasePRNewswire
Compugen to Participate in 2026 Stifel Virtual Targeted Oncology Forum
- Press releasePRNewswire
Compugen to Release First Quarter 2026 Results on Monday, May 18, 2026
- Press releasePRNewswire
Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- News
Earnings Breakdown: Compugen Q4
- News
Compugen Q4 EPS $0.60 Beats $0.05 Estimate, Sales $67.332M Beat $1.357M Estimate
- Press releasePRNewswire
Compugen Reports Fourth Quarter and Full Year 2025 Results
- News
Earnings Scheduled For March 2, 2026
- News
Uncovering Potential: Compugen's Earnings Preview
- Press releasePRNewswire
Compugen to Participate in Upcoming Investor Conferences
- Press releasePRNewswire
Compugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026
- Press releasePRNewswire
Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors
- NewsAvi Kapoor
This Applied Digital Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday
- News
Compugen Agrees With AstraZeneca To Monetize Portion Of Compugen's Rilvegostomig Future Royalties
- Press releasePRNewswire
Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- News
Compugen Q3 EPS $(0.07) Beats $(0.09) Estimate, Sales $1.891M Beat $1.469M Estimate
- Press releasePRNewswire
Compugen Reports Third Quarter 2025 Results
- Press releasePRNewswire
Compugen to Participate in Stifel 2025 Healthcare Conference
- Press releasePRNewswire
Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025
- Press releasePRNewswire
Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025
- Press releasePRNewswire
Compugen to Present at SITC 2025
- Press releasePRNewswire
Compugen to Present Research at the Single Cell Genomics 2025 Conference
- Press releasePRNewswire
Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference
- News
Uncovering Potential: Compugen's Earnings Preview
- Press releasePRNewswire
Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing Technology
- Press releasePRNewswire
Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors
- Press releasePRNewswire
Compugen Reports Third Quarter 2024 Results
- Press releasePRNewswire
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.